Clinical Trial Detail

NCT ID NCT02787005
Title Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

prostate adenocarcinoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.